Related Experiment Video

Updated: Oct 8, 2026

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection
05:55

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Published on: May 7, 2020

Failure of alpha-melanocyte stimulating hormone to attenuate cerebral complications in experimental pneumococcal

S Kastenbauer1, U Koedel, T Brzoska

  • 1Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians University of Munich, Marchioninistrasse 15, 81377, Munchen, Germany.

Journal of Neuroimmunology
|April 20, 2001
PubMed

Insights

Alpha-melanocyte-stimulating hormone (alpha-MSH) did not improve outcomes in a rat model of pneumococcal meningitis. Systemic alpha-MSH did reduce central nervous system leukocyte accumulation, but did not affect other disease complications.

Area of Science:

  • Neuroimmunology
  • Infectious Diseases
  • Pharmacology

Background:

  • Alpha-melanocyte-stimulating hormone (alpha-MSH) is a neuroimmunomodulatory peptide with anti-inflammatory properties.
  • Bacterial meningitis involves significant neuroinflammation and blood-brain barrier disruption.
  • alpha-MSH's potential therapeutic role in meningitis warrants investigation.

Purpose of the Study:

  • To evaluate the efficacy of alpha-MSH in a rat model of pneumococcal meningitis.
  • To determine if alpha-MSH administration impacts key meningitis pathophysiology markers.
  • To assess the effect of alpha-MSH on central nervous system (CNS) inflammation and disease severity.

Main Methods:

  • Rats were intracisternally infected with Streptococcus pneumoniae.
  • Treatment with systemic or intracisternal alpha-MSH commenced 6 hours post-infection.
  • Evaluated blood-brain barrier integrity, intracranial pressure, cytokine levels, bacterial titers, and clinical parameters.

Main Results:

  • alpha-MSH treatment did not alter blood-brain barrier disruption, intracranial pressure, brain cytokine concentrations, or CSF bacterial titers.
  • Systemic alpha-MSH administration, but not intracisternal, slightly reduced CNS leukocyte accumulation.
  • Despite increased CNS alpha-MSH levels, no significant improvement in overall disease severity was observed.

Conclusions:

  • Systemic alpha-MSH can inhibit leukocyte extravasation into the CNS during meningitis.
  • alpha-MSH does not attenuate the primary intracranial complications associated with bacterial meningitis.
  • Further research is needed to explore the therapeutic potential of alpha-MSH in neuroinflammatory conditions.

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...